Short‐Term Efficacy and Safety of Oral Selective Orexin‐2 Receptor Agonists in Narcolepsy Type 1: An Updated Systematic Review and Meta‐Analysis of Randomized Trials
Neuropsychopharmacology Reports · 2026-12 · 46 (4)
DOI: 10.1002/npr2.70189 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Neuropsychopharmacology Reports, online erschienen am 17.11.2026. Verfasst von Aasim Ali und 10 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Selective orexin‐2 receptor (OX2R) agonists show efficacy. Between‐trial variability and safety uncertainty warrant pooled assessment.
Objective
We evaluated treatment effects in narcolepsy Type 1. We assessed pooled benefits, harms, and efficacy robustness.
Methods
Five databases and two trial registries were searched. Searches extended through September 15, 2026. Eligible trials evaluated repeated‐dose oral selective OX2R agonists. Trials were randomized, parallel, double‐blind, and placebo‐controlled. Shared‐placebo comparisons were combined using generalized least squares. Random‐effects models pooled efficacy and overall adverse events. Between‐study variance used restricted maximum‐likelihood estimation. Confidence intervals used the modified Knapp–Hartung method. Sparse safety outcomes used Mantel–Haenszel common‐effect risk ratios. Risk of bias was assessed using RoB 2.
Results
Five trials randomized 550 participants over 6–12 weeks. Efficacy estimates compared active treatment with placebo. Maintenance of Wakefulness Test improvement averaged 21.91 min (95% CI: 15.11–28.70; I 2 = 84.5%). Epworth Sleepiness Scale scores decreased by 9.28 points (95% CI: 7.96–10.60; I 2 = 0%). Weekly cataplexy rates were lower with treatment (incidence rate ratio, 0.34; 95% CI: 0.22–0.55; I 2 = 36.1%). Treatment‐emergent adverse events increased (risk ratio, 1.89; 95% CI: 1.44–2.48). Insomnia, urinary symptoms, and salivary hypersecretion increased. Adverse‐event discontinuation estimates remained imprecise (risk ratio, 3.73; 95% CI: 0.50–28.03). Excluding TAK‐994 yielded similar efficacy estimates. Residual wakefulness heterogeneity remained substantial ( I 2 = 69.9%).
Conclusion
Studied regimens improved wakefulness, sleepiness, and cataplexy. Benefits persisted after excluding TAK‐994. However, wakefulness effects varied substantially across trials. Treatment increased several clinically relevant adverse events. Long‐term safety and uncommon harms remain uncertain.
Zitieren
APA
Ali, A., Sajjad, A., Talha, M., Waqar, K., Tanveer, A., Mehmood, A., Wahab, A., Shahid, M. A., Rana, O. U. R., Abdullah, A., & Sharma, M. K. (2026). Short‐Term Efficacy and Safety of Oral Selective Orexin‐2 Receptor Agonists in Narcolepsy Type 1: An Updated Systematic Review and Meta‐Analysis of Randomized Trials. Neuropsychopharmacology Reports, 46(4). https://doi.org/10.1002/npr2.70189
Vancouver
Ali A, Sajjad A, Talha M, Waqar K, Tanveer A, Mehmood A, et al. Short‐Term Efficacy and Safety of Oral Selective Orexin‐2 Receptor Agonists in Narcolepsy Type 1: An Updated Systematic Review and Meta‐Analysis of Randomized Trials. Neuropsychopharmacology Reports. 2026;46(4). doi:10.1002/npr2.70189
BibTeX
@article{Ali2026,
author = {Ali, Aasim and Sajjad, Ali and Talha, Muhammad and Waqar, Khadija and Tanveer, Anousha and Mehmood, Ammara and Wahab, Abdul and Shahid, Muhammad Ahmad and Rana, Obaid Ur Rehman and Abdullah, Armaghana and Sharma, Mukesh Kumar},
title = {Short‐Term Efficacy and Safety of Oral Selective Orexin‐2 Receptor Agonists in Narcolepsy Type 1: An Updated Systematic Review and Meta‐Analysis of Randomized Trials},
journal = {Neuropsychopharmacology Reports},
year = {2026},
volume = {46},
number = {4},
doi = {10.1002/npr2.70189}
}
EUVIMED